Kiniksa Pharmaceuticals Receives U.S. FDA Orphan Drug Designation for KPL-387 in Pericarditis Treatment’
LONDON, Oct. 17, 2025 Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA), a biopharmaceutical company focused on developing and commercializing novel therapies for diseases with unmet needs, particularly in the cardiovascular space, has announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to KPL-387. This designation pertains to the treatment of pericarditis, including its recurrent form.
KPL-387 is an independently developed monoclonal antibody that targets the human interleukin-1 receptor 1 (IL-1R1). By inhibiting the signaling activity of the cytokines interleukin-1 (IL-1), the medication offers a new approach in managing pericarditis, a condition characterized by inflammation of the pericardium, which can lead to frequent recurrences, pain, and potentially severe complications if not effectively managed.
Orphan Drug Designation by the FDA is a significant milestone for Kiniksa as it not only acknowledges the therapeutic potential of KPL-387 in treating a rare condition but also provides potential benefits such as tax credits for clinical trials, user fee waivers, and market exclusivity for seven years post-approval.
Financially, Kiniksa Pharmaceuticals displayed a noteworthy improvement in its second quarter of 2025. The company reported a return on equity (ROE) of 1.05%, marking a considerable advance from the previous negative average ROE of -13.01% and the -3.83% recorded in the first quarter of 2025. This positive growth in ROE is attributed to the increase in net income during the quarter.
Within the Major Pharmaceutical Preparations industry, only two other companies outperformed Kiniksa in terms of ROE. Kiniksa’s overall ROE ranking has shown remarkable progress, moving up to 317 in the second quarter from a position of 2267 in the first quarter of 2025.
This accomplishment in both the clinical and financial arenas underscores Kiniksa’s continued commitment to advancing therapeutic options for cardiovascular diseases and providing value to its stakeholders.
Comments